Treace Medical Concepts Inc TMCI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Treace Highlights New Product Innovations and Updated Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024
-
Treace Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Treace Medical Concepts Reports Second Quarter 2024 Financial Results
-
Treace to Report Second Quarter 2024 Financial Results on August 6, 2024
Trading Information
- Previous Close Price
- $5.80
- Day Range
- $5.74–6.07
- 52-Week Range
- $3.92–15.98
- Bid/Ask
- $5.67 / $5.75
- Market Cap
- $358.84 Mil
- Volume/Avg
- 632,633 / 782,366
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.80
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 227
- Website
- https://www.treace.com
Comparables
Valuation
|
Metric
|
TMCI
|
SIBN
|
603301
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 22.34 |
Price/Book Value | 3.20 | 3.37 | 1.09 |
Price/Sales | 1.80 | 3.62 | 1.54 |
Price/Cash Flow | — | — | 9.31 |
Price/Earnings
TMCI
SIBN
603301
Financial Strength
|
Metric
|
TMCI
|
SIBN
|
603301
|
|---|---|---|---|
Quick Ratio | 2.71 | 7.99 | 1.57 |
Current Ratio | 3.86 | 9.17 | 2.24 |
Interest Coverage | −12.36 | −12.97 | 5.28 |
Quick Ratio
TMCI
SIBN
603301
Profitability
|
Metric
|
TMCI
|
SIBN
|
603301
|
|---|---|---|---|
Return on Assets (Normalized) | −15.89% | −6.03% | 1.65% |
Return on Equity (Normalized) | −28.96% | −8.10% | 2.34% |
Return on Invested Capital (Normalized) | −19.43% | −8.97% | 1.91% |
Return on Assets
TMCI
SIBN
603301
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Rrlfgjrwm | Gvsrbq | $195.6 Bil | |||
| Stryker Corp
SYK
| Gvlcgdgnh | Fpn | $137.3 Bil | |||
| Boston Scientific Corp
BSX
| Hqgwzbjsx | Sljbhd | $122.7 Bil | |||
| Medtronic PLC
MDT
| Cppvqmt | Swrbmf | $114.6 Bil | |||
| Edwards Lifesciences Corp
EW
| Gfdxkthx | Jmmxsh | $40.1 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Zqng | Wrg | $30.7 Bil | |||
| DexCom Inc
DXCM
| Ftjthxxmw | Htlfj | $27.0 Bil | |||
| Steris PLC
STE
| Npnqrmxz | Ygvzkx | $23.6 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Bkstkhbgym | Rpwr | $22.0 Bil | |||
| Insulet Corp
PODD
| Mkjwgjvgp | Yxsspqd | $16.3 Bil |
United States